CannBioRx Life Sciences (ATNFW) has had the highest return since August 1, 2025 by a micro-cap US stock, returning 3,493.8%.
| ASSET | % RETURN |
|---|---|
CannBioRx Life Sciences (ATNFW) | 3,493.75% |
Catheter Precision (VTAK) | 1,727.56% |
Bolt Projects (BSLK) | 240% |
Cognition Therapeutics (CGTX) | 198.83% |
BioXcel Therapeutics (BTAI) | 186.14% |
Trinity Biotech (TRIB) | 172.86% |
Equillium (EQ) | 145.03% |
Atlantic International Corp Common Stock (ATLN) | 144.08% |
Kindly (NAKA) | 113.66% |
Thayer Ventures Acquisition (TVACW) | 113.14% |
Medirom Healthcare Technologies (MRM) | 103.6% |
OneMedNet (ONMD) | 100.21% |
X4 Pharmaceuticals (XFOR) | 98.73% |
Advent Technologies (ADN) | 97.85% |
Matinas BioPharma (MTNB) | 94.12% |
Dogness International Corp Class A (DOGZ) | 88.52% |
mF International Limited Ordinary Shares (MFI) | 86.25% |
Verb Technology (VERB) | 80.96% |
Sonoma Pharmaceuticals (SNOA) | 80.48% |
Babcock & Wilcox Enterprises (BW) | 76.84% |
Expion360 (XPON) | 75.65% |
InfuSystems (INFU) | 72.96% |
Zivo Bioscience (ZIVO) | 72.54% |
Ovid Therapeutics (OVID) | 72.23% |
Puma Biotechnology (PBYI) | 71.61% |
Micro-cap stocks are treated as having a market cap of <= $300M.
